NASDAQ:EDSA

Edesa Biotech Stock Forecast

etoro logo Buy EDSA
*Your capital is at risk
$5.24
-0.0300 (-0.569%)
At Close: Aug 10, 2026

Should you buy EDSA stock?

Last updated:

Based on market data through , StockInvest.us rates Edesa Biotech, Inc. (EDSA) as a Strong Sell Candidate with a technical score of -6.19 on its -10 to +10 scale. This is a downgrade from Sell in the previous daily evaluation.

  • Sell signal since
  • Price since signal Down 31.41%
  • 3-month trend forecast Down 54.78%
  • Strong Sell Candidate -6.19
AI Analysis AI Analysis of EDSA AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add EDSA to Watchlist?
  • Easy Tracking In The Watchlist
PDF

Edesa Biotech, Inc. stock downgraded to Strong Sell Candidate
(Market data through Aug 10, 2026)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Sell candidate since Jun 23, 2026 Loss -31.41%

The Edesa Biotech, Inc. stock price fell by -0.569% on the last day (Monday, 10th Aug 2026) from $5.27 to $5.24. During the last trading day the stock fluctuated 7.74% from a day low at $5.23 to a day high of $5.64. The price has fallen in 6 of the last 10 days and is down by -2.06% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -17 thousand shares and in total, 37 thousand shares were bought and sold for approximately $194.00 thousand.

The stockhas broken the very wide and falling short-term trend up. Firstly a slower falling rate is indicated, but this may very well be an early signal of a trend shift. On the reaction, there will be support on the roof of the current trend broken, which is $5.16, a level that may pose a second chance to hit a runner. According to fan-theory $9.62 will be the next possible trend-top level and thereby pose a resistance level that may not be broken at the first attempt.

EDSA Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Edesa Biotech, Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $6.41. On a fall, the stock will find some support from the short-term average at $5.20. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Friday, June 26, 2026, and so far it has fallen -36.02%. Further fall is indicated until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss for Edesa Biotech, Inc. stock

Edesa Biotech, Inc. finds support from accumulated volume at $5.21 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk". During the last day, the stock moved $0.405 between high and low, or 7.74%. For the last week the stock has had daily average volatility of 10.45%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (EDSA) For The Upcoming Trading Day Of Tuesday 11th

For the upcoming trading day on Tuesday, 11th we expect Edesa Biotech, Inc. to open at $5.37, and during the day (based on 14 day Average True Range), to move between $4.93 and $5.55, which gives a possible trading interval of +/-$0.619 (+/-12.55%) up or down from last closing price. If Edesa Biotech, Inc. takes out the full calculated possible swing range there will be an estimated 12.55% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $5.21 (0.57%) than the resistance at $5.37 (2.48%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Earnings coming up

Edesa Biotech, Inc. will release earnings BMO on Friday, August 14, 2026.The consensus among the analysts for the expected earnings (EPS) is -$0.440. We will update the financials statements for Edesa Biotech, Inc., that can be found here as soon as the records are public. Our systems has calculated a possible swing of +/- 7.91% in the first trading day after earnings release.

Is Edesa Biotech, Inc. stock A Buy?

Edesa Biotech, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -6.186 Strong Sell Candidate Downgraded

Predicted Fair Opening Price

Predicted fair opening price on August 11, 2026 - $5.37 ( 2.45%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

EDSA Performance

Trading levels for EDSA

StockInvest.us
Full Access. No Commitment. Up to 14 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 5.77 10.18%
R2 5.62 7.23%
R1 5.52 5.40%
Price 5.24
S1 5.21 -0.503%
S2 5.12 -2.33%
S3 4.96 -5.28%

Accumulated Volume Support & Resistance Levels

Level Price
R3 5.65 7.82%
R2 5.46 4.20%
R1 5.37 2.48%
Price 5.24
S1 5.21 -0.573%
S2 4.97 -5.15%
S3 4.94 -5.73%

FAQ

What is the symbol for Edesa Biotech, Inc. Stock and on which exchange is it traded?
The symbol for Edesa Biotech, Inc. is EDSA and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Edesa Biotech, Inc. Stock?
Based on market data through Aug 10, 2026, StockInvest.us rates Edesa Biotech, Inc. (EDSA) as a Strong Sell Candidate with a technical score of -6.19 on its -10 to +10 scale. This is a downgrade from Sell in the previous daily evaluation. Since the Sell signal began on Jun 23, 2026, the price has fallen 31.41%. The current 3-month trend forecast projects a fall of 54.78%.

How to buy Edesa Biotech, Inc. Stock?
Edesa Biotech, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Edesa Biotech, Inc. Stock.

What's the current price of Edesa Biotech, Inc. Stock?
As of the end of day on the Aug 10, 2026, the price of an Edesa Biotech, Inc. (EDSA) share was $5.24.

What is the 52-week high and low for Edesa Biotech, Inc. Stock?
The 52-week high for Edesa Biotech, Inc. Stock is $20.32 and the 52-week low is $0.720.

What is the market capitalization of Edesa Biotech, Inc. Stock?
As of the Aug 10, 2026, the market capitalization of Edesa Biotech, Inc. is 50.478M.

When is the next earnings date for Edesa Biotech, Inc.?
The upcoming earnings date for Edesa Biotech, Inc. is Aug 14, 2026.
Click to get the best stock tips daily for free!
ABOUT EDESA BIOTECH, INC.
Edesa Biotech
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chro...
GOLDEN STAR
Ticker Change Signal Date
GPOR
$158.45
6.03% Aug 06
FCX
$62.63
12.61% Jul 31
BIIB
$202.19
2.44% Jul 24
TSCO
$30.32
14.18% Jul 23
S
SW
$43.71
8.88% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE